Dynamics of natriuretic peptide and inflammatory markers in patients with congestive heart failure and different response to cardiac resynchronization therapy

The aim: To assess the dynamics of N-terminal pro-brain natriuretic peptide (NT-proBNP) and inflammatory markers in patients with congestive heart failure (CHF) and different response to cardiac resynchronization therapy (CRT). A total of 37 patients (mean age of 55.1±7.1 years, 81.1% men) with CHF (67.6% ischemic and 32.4% non-ischemic etiology) were examined at baseline, 1 month, and 6 months after CRT: NT-proBNP, tumor necrosis factor-α, interleukin-1β, interleukin-6, C-reactive protein and an echocardiogram. According to the dynamics of left ventricular end-systolic volume, patients were divided into responders (>15%; n=23) and non-responders (<15%; n=14). In responders, NT-proBNP decreased from 2402.4±1483.5 to 1131.1±547.8 pg/mL after 1 month (p=0.007) and to 871.1±556.7 pg/mL after 6 months (р=0.002). In non-responders, the levels of NT-proBNP did not change significantly. Responders demonstrated a tendency to reduction of all inflammatory markers: tumor necrosis factor-α (p=0.094), interleukin-6 (p=0.074), interleukin-1β (p=0.081), and C-reactive protein (p=0.072) after 6 months of CRT. In non-responders, inflammatory markers did not change significantly. Decrease of NT-proBNP and probably the reduction of inflammatory markers can be used for the assessment of CRT effect.

сердечная недостаточность, сердечная ресинхронизирующая терапия, медиаторы воспаления, натрийуретический пептид, heart failure, cardiac resynchronization therapy, inflammatory markers, natriuretic peptide

1. Егорова Е.Н., Калинкин М.Н., Мазур Е.С. Иммунные механизмы в патогенезе хронической сердечной недостаточности // Патологическая физиология и экспериментальная терапия. - 2012. - № 2. - С. 56-61.

2. Кузнецов В.А. Сердечная ресинхронизирующая терапия: избранные вопросы. - Абис, 2007. - 128 с.

3. Кузнецов В.А., Колунин Г.В., Харац В.Е. и др. Регистр проведенных операций сердечной ресинхронизирующей терапии. - Свидетельство о государственной регистрации базы данных № 2010620077, зарегистрировано в Реестре базы данных 1 февраля 2010 года.

4. Кузнецов В.А., Виноградова Т.О., Енина Т.Н. и др. Влияние сердечной ресинхронизирующей терапии на выживаемость пациентов с кардиомиопатией ишемического и неишемического генеза в клинической практике // Тер. архив. - 2012. - № 8. - С. 52-56.

5. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Рекомендации ВНОК и ОССН по диагностике и лечению хронической сердечной недостаточности (третий пересмотр) // Сердечная недостаточность. - 2010. - № 1. - С. 3-62.

6. Харченко Е.П. Сердечная недостаточность: патогенетический континуум и биомаркеры // Кардиология. - 2012. -№ 3. - С. 53-64.

7. Berger R., Shankar A., Fruhwald F. et al. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study // Eur. Heart J. - 2009. - Vol. 30, No. 17. - С. 2109-2116.

8. Bielecka-Dabrowa A., Goch J.H., Mikhailidiset D.P. et al. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy // Medical science monitor. - 2009. - Vol. 15, No. 12. - P. 12-23.

9. Braun M.U., Rauwolf T., Zerm T. et al. Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones // Heart. - 2005. - Vol. 91, No. 5. - P. 601-605.

10. Brignole M., Auricchio A., Baron-Esquiviaset G. et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) // Eur. Heart J. - 2013. - Vol. 34(29). - P. 2281-2329.

11. Candia M., Villacorta Junior H., Mesquita E.T. Immune-inflammatory activation in heart failure // Arquivos Brasileiros de Cardiologia. - 2007. - Vol. 89, No. 3. - P. 201-208.

12. Ding L.G., Hua W., Zhang S. et al. Decrease of plasma N-terminal pro В-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure // Chinese Medical Journal. - 2009. - Vol. 122, No. 6. - Р. 617-621.

13. Dong Y.X., Burnett Jr.J.C., Chen H.H. et al. Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure // Journal of Interventional Cardiac Electrophysiology. - 2011. - Vol. 30, No. 3. - P 241-249.

14. Gullestad L., Ueland T., Vingeet L.E. et al. Inflammatory cytokines in heart failure: mediators and markers // Cardiology. - 2012. -Vol. 122, No. 1. - P. 23-35.

15. Hofmann U., Frantz S. How can we cure a heart “in flame”? A translational view on inflammation in heart failure // Basic research in cardiology. - 2013. - Vol. 108, No. 4. - P. 1-19.

16. Kuznetsov V.A., Soldatova A.M., Enina T.N. et al. Dynamics of natriuretic peptide and inflammatory markers in patients with implanted devices for cardiac resynchronization therapy // Eur. J. Heart Failure - 2014. - Vol. 16, Issue s2. - P. 169.

17. Oikonomou E., Tousoulis D., Siasos G. et al. The role of inflammation in heart failure: new therapeutic approaches // Hellenic J. Cardiol. - 2011. - Vol. 52, No. 1. - P. 30-40.

18. Rostagno C., Olivo G., Comeglio M. et al. Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure comparison with other methods of functional evalution // Eur. J. Heart Failure. - 2003. - Vol. 5. - Р. 247-252.

19. Shinohara T., Takahashi N., Saito S. et al. Effect of cardiac resynchronization therapy on cardiac sympathetic nervous dysfunction and serum C-reactive protein level // Pacing and Clinical Electrophysiology. - 2011. - Vol. 34, No. 10. - P. 1225-1230.

20. Tarquini R., Guerra C.T., Porciani M.C. et al. Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure // Cardiol. J. - 2009. - Vol. 16, No. 6. - P. 545-552.

21. Yu C.M., Sanderson J.E., Gorcsan J. Echocardiography, dyssynchrony, and the response to cardiac resynchronization therapy // Eur. Heart J. - 2010. - Vol. 31, No. 19. - P. 2326-2337.

22. Voors A.A., Dorhout B., Van der Meer P. The potential role of valsartan+ AHU377 (LCZ696) in the treatment of heart failure // Expert opinion on investigational drugs. - 2013. - No. 0. - С. 1-7.